Indispensable or intolerable? Methotrexate in patients with rheumatoid and psoriatic arthritis: A retrospective review of discontinuation rates from a large UK cohort

Clinical Rheumatology

Volumn 33, Issue 5, 2014, Pages 609-614

  Nikiphorou, Elena ^a   Negoescu, Andra ^a   Fitzpatrick, John D ^a   Goudie, Calum T ^a   Badcock, Andrew ^a   Ösẗor, Andrew J K ^a   Malaviya, Anshuman P ^b  

^a CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b BASILDON HOSPITAL   (United Kingdom)

Author keywords

Discontinuation; Methotrexate; Psoriatic arthritis; Rheumatoid arthritis; Side effects; Withdrawal

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; GLUCOSE; METHOTREXATE; ANTIRHEUMATIC AGENT;

ABDOMINAL PAIN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; ANXIETY; BLOATING; BLOOD CELL COUNT; CHEST INFECTION; CHRONIC DISEASE; COUGHING; DEPRESSION; DIARRHEA; DIZZINESS; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; FATIGUE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; KIDNEY DYSFUNCTION; LEUKOPENIA; LIVER FUNCTION TEST; LOSS OF APPETITE; MAJOR CLINICAL STUDY; MEDICATION COMPLIANCE; MOUTH ULCER; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; PSORIATIC ARTHRITIS; RESPIRATORY TRACT DISEASE; RETROSPECTIVE STUDY; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SKIN NODULE; SLEEP DISORDER; TENESMUS; THROMBOCYTOPENIA; TREATMENT WITHDRAWAL; ULCER; UNITED KINGDOM; UPPER RESPIRATORY TRACT INFECTION; VOMITING; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; PATIENT COMPLIANCE; TIME; TREATMENT OUTCOME;

ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; GREAT BRITAIN; HUMANS; METHOTREXATE; PATIENT COMPLIANCE; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84902372533     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-014-2546-x     Document Type: Review

References (25)

1. Bathon J, Robles M, Ximenes AC, Nayiager S et al (2011) Sustained disease remission and inhibition of radiographic progression in methotrexate-naive patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes. Ann Rheum Dis 70:1949-1956
2. Schiff M, Keiserman M, Codding C et al (2008) Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multicentre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 67:1096-1103
3. Lu LJ, Bao CD, Dai M et al (2009) Multicenter, randomized, double-blind, controlled trial of treatment of active rheumatoid arthritis with T-614 compared with methotrexate. Arthritis Rheum 61:979-987
4. Smolen J, Landewe RB, Mease P et al (2009) Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis 68:797-804
5. van de Heijde D, Klareskog L, Rodriguez-Valverde V et al (2006) Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 54:1063-1074 (Pubitemid 43672919)
6. Salliot C, van der Heijde D (2009) Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis 68:1100-1104
7. Katchamart W, Trudeau J, Phumethum V et al (2010) Methotrexate monotherapy versus methotrexate combination therapy with non-biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis. Cochrane Database Syst Rev 14(4):CD008495
8. Bologna C, Jorgensen C, Sany J (1997) Methotrexate as the initial second-line disease modifying agent in the treatment of rheumatoid arthritis patients. Cl Exp Rheum 15:597-601 (Pubitemid 27501644)
9. Keysser M, Keysser G, Keysser C (1999) Long-term application of disease modifying antirheumatic drugs (DMARD). A single-center, observational study of 1681 patients with rheumatoid arthritis (RA). Z Rheumatol 58:267-276 (Pubitemid 29526614)
10. Emery P, Breedveld FC, Lemmel EM et al (2000) A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology 39:655-665 (Pubitemid 30459953)
11. van Ede AE, Laan RF, Rood MJ et al (2001) Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 44:1515-1524 (Pubitemid 32651731)
12. Smolen JS, Aletaha D, Bijlsma JWJ et al (2010) Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 69:631-637
13. Gäwert L, Hierse F, Zink A et al (2011) How well do patient reports reflect adverse drug reactions reported by rheumatologists? Agreement of physician- and patient-reported adverse events in patients with rheumatoid arthritis observed in the German biologics register. Rheumatology 50:152-160
14. Shiroky JB, Neville C, Esdaile JM et al (1993) Low-dose methotrexate with leucovorin (folinic acid) in the management of rheumatoid arthritis. Results of a multicenter randomized, double-blind, placebo-controlled trial. Arthritis Rheum 36:795-803 (Pubitemid 23175621)
15. Caro JJ, Salas M, Speckman JL et al (1999) Persistence with treatment for hypertension in actual practice. CMAJ 160:31-37 (Pubitemid 29054224)
16. Mariette X, Cazals-Hatem D, Warszawki J et al (2002) Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood 99:3909-3915 (Pubitemid 35332027)
17. Owen SA, Lunt M, Bowes J, et al (2011) MTHFR gene polymorphisms and outcome of methotrexate treatment in patients with rheumatoid arthritis: analysis of key polymorphisms and meta-analysis of C677T and A1298C polymorphisms. Pharmacogenomics J 13:137-147
18. Lee YH, Song GG (2010) Associations between the C677T and A1298C polymorphisms of MTHFR and the efficacy and toxicity of methotrexate in rheumatoid arthritis: a meta-analysis. Clin Drug Investig 30:101-108
19. Fisher MC, Cronstein BN (2011) Metaanalysis of methylenetetrahydrofolate reductase (MTHFR) polymorphisms affecting methotrexate toxicity. J Rheumatol 36:539-545
20. Urano W, Taniguchi A, Yamanaka H et al (2002) Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics 12:183-190 (Pubitemid 34596782)
21. Cáliz R, del Amo J, Balsa A et al (2012) The C677T polymorphism in the MTHFR gene is associated with the toxicity of methotrexate in a Spanish rheumatoid arthritis population. Scand J Rheumatol 41:10-14
22. Weisman MH, Furst DE, Park GS et al (2006) Risk genotypes in folate-dependent enzymes and their association with methotrexate-related side effects in rheumatoid arthritis. Arthritis Rheum 54:607-612 (Pubitemid 43228638)
23. Berkun Y, Levartovsky D, Rubinow A et al (2004) Methotrexate related adverse effects in patients with rheumatoid arthritis are associated with the A1298C polymorphism of the MTHFR gene. Ann Rheum Dis 63:1227-1231 (Pubitemid 39273498)
24. Spyridopoulou KP, Dimou NL, Hamodrakas SJ et al (2012) Methylene tetrahydrofolate reductase gene polymorphisms and their association with methotrexate toxicity: a meta-analysis. Pharmacogenet Genomics 22:117-133
25. Wluka A, Buchbinder R, Mylvaganam A et al (2000) Longterm methotrexate use in rheumatoid arthritis: 12 year follow up of 460 patients treated in community practice. J Rheumatol 27:1864-1871 (Pubitemid 30670479)